Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systematic literature review of particle therapy costing: two decades of evidence on costing methods and analytical assumptions.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Ten-year update on the European Association of Urology Robotic Section (ERUS) fellowship training for robot-assisted radical prostatectomy.

BJUI compass·2026
Same author

Management of older adults with colorectal cancer - The state-of-the-art in 2026.

Journal of geriatric oncology·2026
Same author

Development of the Transurethral Treatment Intermediate Skills Curriculum for TURP (Step 2P): A Cognitive Task Analysis and Delphi Consensus from the European School of Urology.

Journal of endourology·2026
Same author

Multi-omic biomarkers of neoadjuvant treatment response in rectal cancer: A narrative review.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

Young onset rectal cancer (YORC): a descriptive tertiary center analysis.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026

Related Experiment Video

Updated: Apr 12, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.3K

Hypofractionated palliative radiotherapy for bladder cancer.

Piet Dirix1,2, Sofie Vingerhoedt3, Steven Joniau4

  • 1Department of Radiation Oncology, Leuvens Kankerinstituut (LKI), University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium. piet.dirix@gza.be.

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|May 16, 2015
PubMed
Summary

This study found that hypofractionated palliative radiotherapy for bladder cancer effectively controls hematuria in most patients. The treatment demonstrated acceptable toxicity, offering long-term symptom relief for bladder cancer patients.

Keywords:
Altered fractionationBladder cancerPalliationRadiotherapy

More Related Videos

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.9K
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

16.3K

Related Experiment Videos

Last Updated: Apr 12, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.3K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.9K
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

16.3K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Urology

Background:

  • Bladder cancer management often requires palliative radiotherapy.
  • Hypofractionated schedules offer potential benefits in palliative settings.

Purpose of the Study:

  • To assess hematuria-free survival after hypofractionated palliative radiotherapy for bladder cancer.
  • To evaluate acute and late toxicity associated with this treatment regimen.

Main Methods:

  • A cohort of 44 patients with urothelial carcinoma of the bladder received palliative radiotherapy.
  • The treatment involved a total dose of 34.5 Gy in six weekly fractions of 5.75 Gy.

Main Results:

  • 91% of patients remained hematuria-free at a mean follow-up of 10 months.
  • Mean hematuria-free survival was 13 months.
  • Severe acute and late urinary toxicity occurred in 9% and 19% of patients, respectively.

Conclusions:

  • Hypofractionated palliative radiotherapy is a viable option for bladder cancer.
  • This schedule provides effective and durable hematuria palliation with acceptable toxicity.